NYSE:RCUS Arcus Biosciences (RCUS) Stock Price, News & Analysis $9.32 -0.18 (-1.84%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$9.28 -0.04 (-0.38%) As of 08/7/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcus Biosciences Stock (NYSE:RCUS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arcus Biosciences alerts:Sign Up Key Stats Today's Range$9.22▼$10.7450-Day Range$7.94▼$10.2152-Week Range$6.50▼$18.98Volume1.48 million shsAverage Volume681,611 shsMarket Capitalization$986.37 millionP/E RatioN/ADividend YieldN/APrice Target$21.14Consensus RatingModerate Buy Company Overview Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. Read More Arcus Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreRCUS MarketRank™: Arcus Biosciences scored higher than 42% of companies evaluated by MarketBeat, and ranked 602nd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingArcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArcus Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Arcus Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arcus Biosciences are expected to decrease in the coming year, from ($3.15) to ($4.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.55% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Arcus Biosciences has recently decreased by 8.39%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.55% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Arcus Biosciences has recently decreased by 8.39%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.26 News SentimentArcus Biosciences has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arcus Biosciences this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for RCUS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of Arcus Biosciences is held by insiders.Percentage Held by Institutions92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcus Biosciences' insider trading history. Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RCUS Stock News HeadlinesArcus (RCUS) Q2 Revenue Jumps 310%August 6 at 11:05 PM | fool.comArcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline UpdateAugust 6 at 5:12 PM | gurufocus.comCritical AI announcement set to ignite AI 2.0 Markets are jittery. Rallies fade. Sectors rotate overnight. And the true impact of new tariffs and policy shifts hasn’t even hit the data yet. That’s why smart traders are turning to a strategy built for exactly this kind of market—fast, simple, and designed to react to real price action, not predictions. | Timothy Sykes (Ad)Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline UpdateAugust 6 at 4:05 PM | businesswire.comArcus Biosciences’ Pancreatic Cancer Drug Quemliclustat Receives Orphan Drug Designation from FDAJuly 31, 2025 | msn.comGilead and Arcus Biosciences’ Promising Lung Cancer Study: Market ImplicationsJuly 24, 2025 | msn.comArcus Biosciences Announces New Employment Inducement GrantsJuly 24, 2025 | businesswire.comPrecision BioSciences shares climb after FDA grants orphan drug statusJuly 23, 2025 | msn.comSee More Headlines RCUS Stock Analysis - Frequently Asked Questions How have RCUS shares performed this year? Arcus Biosciences' stock was trading at $14.89 at the start of the year. Since then, RCUS stock has decreased by 37.4% and is now trading at $9.3150. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) released its quarterly earnings results on Wednesday, August, 6th. The company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.03. The business's revenue for the quarter was up 310.3% compared to the same quarter last year. When did Arcus Biosciences IPO? Arcus Biosciences (RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO. Who are Arcus Biosciences' major shareholders? Arcus Biosciences' top institutional investors include Nordea Investment Management AB (0.30%), Parallel Advisors LLC (0.08%), State of Alaska Department of Revenue (0.04%) and VIRGINIA RETIREMENT SYSTEMS ET Al (0.03%). Insiders that own company stock include Gilead Sciences, Inc, Terry J Rosen, Juan C Jaen, Jennifer Jarrett, Robert C Goeltz II, Carolyn C Tang, Yasunori Kaneko and Alexander Azoy. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings8/06/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSE:RCUS CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees500Year FoundedN/APrice Target and Rating Average Price Target for Arcus Biosciences$21.14 High Price Target$33.00 Low Price Target$13.00 Potential Upside/Downside+127.0%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($4.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$283 million Net Margins-109.56% Pretax Margin-258.28% Return on Equity-56.55% Return on Assets-25.13% Debt Debt-to-Equity Ratio0.09 Current Ratio5.37 Quick Ratio5.37 Sales & Book Value Annual Sales$258 million Price / Sales3.82 Cash FlowN/A Price / Cash FlowN/A Book Value$5.30 per share Price / Book1.76Miscellaneous Outstanding Shares105,890,000Free Float95,720,000Market Cap$986.37 million OptionableOptionable Beta0.89 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSE:RCUS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.